$26.04
Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
Assembly Biosciences Announces Upcoming Investor Conference Presentations
Overview
52-week range
$16
$40
43% of range
Avg surprise (last 2)
+33.9%
Avg reaction (last 2)
-3.7%
0% positive
Latest IV / EM
91%
EM ±20.7% · $25 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.54 | $-0.73 | +26.0% | +53.9% | -1.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.72 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-1.33 | — | — | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-1.17 | $-2.01 | +41.8% | — | -6.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.51 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.98 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.66 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-3.29 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-3.88 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | -$0.70 | -$1.33 | +47.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-11M | — | $-11M | $-11M | $-10M | — | $-11M | $-12M |
| Net income | $-9M | — | $-9M | $-10M | $-9M | — | $-10M | $-11M |
| EPS (diluted) | $-0.54 | — | $-0.72 | $-1.33 | $-1.17 | — | $-1.51 | $-1.98 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $31M | $58M | $23M | $24M | $23M | $38M | $28M | $19M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $233M | $255M | $237M | $77M | $96M | $116M | $98M | $113M |
| Total assets | $236M | $258M | $240M | $81M | $99M | $119M | $100M | $115M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $37M | $51M | $57M | $63M | $72M | $86M | $74M | $81M |
| Total equity | $199M | $207M | $183M | $18M | $27M | $33M | $26M | $35M |